|By Marketwired .||
|July 7, 2014 12:22 PM EDT||
GOLDEN, CO -- (Marketwired) -- 07/07/14 -- iSatori, Inc. (OTCQB: IFIT), an emerging leader in the development and marketing of scientifically engineered nutritional supplements for healthier lifestyles, today released the results of a brand-new clinical study on its popular energy pill, Energize, titled "Pharmacokinetics of caffeine administered in a time-release [Energize] versus regular tablet form." The study, which was a double-blind, placebo-controlled, randomized clinical trial (the "gold standard of studies), was performed by the Institute of Exercise Physiology and Wellness at the University of Central Florida (UCF) in Orlando and presented at this year's annual ISSN Conference in Clearwater, Florida on June 21, 2014.
The clinical trial confirms the company's claims for extended energy when Energize is consumed from a single dose. Energize was compared in a double-blind, placebo-controlled, cross-over study to an equivalent dose of caffeine (194 mg) and a placebo. Blood was taken when the products were initially ingested and every subsequent hour for an eight-hour period. The researchers confirmed that while the common caffeine quickly reached its peak after three hours, with Energize, the caffeine didn't reach its peak until six full hours after ingestion and remained present for up to the eight hours. The UCF researchers concluded that absorption following Energize ingestion was both slower and more sustained, which could prolong the effects of caffeine and limit the common caffeine "crash."
Stephen Adelé, founder and Chief Executive Officer of iSatori, commented, "Our driving force as an innovative product leader in the $31-billion nutritional supplements industry is once again solidified by the continued investment we make in taking a science-based approach to our products. This is a true differentiator between us and other companies, and one in which our enlightened customers highly value. Conducting additional clinical studies, such as the two most recently performed on Energize, helps strengthen the confidence our customers and retailers have in our company."
Director of Science and Education for iSatori, David Sandler, also commented, "The data from this study confirmed that our multi-layered time-release tablets [Energize] deliver a steady release of caffeine into the bloodstream, providing a sustained supply of energy without the hard drop off typically seen with large caffeine doses. By reducing the peak and crash typically seen with acute caffeine ingestion, with Energize, our consumers can enjoy the benefit of both a smooth and continued alertness and focus for up to eight hours, during their busy, oftentimes hectic days."
Energize is a sustained-release energy tablet, which contains a proprietary blend of natural caffeine, amino acids, vitamins, and herbs and is available at Walgreens, Duane Reade, Rite Aid, and select Walmart stores nationwide. To learn more about Energize, locate a convenient retailer, and download a $2.00 off coupon, please visit www.TryEnergize.com.
About iSatori, Inc.
iSatori is a consumer products firm that develops and sells nutritional products through online marketing, Fortune 500 retailers, and thousands of retail stores around the world. The Company is headquartered in Golden, Colorado, and its common stock trades on the OTCQB under the symbol "IFIT." More information about the Company is available at http://www.isatori.com.
Statements made in this news release relating to the Company's future sales, expenses, revenue, product developments, and all other statements except statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We have used the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," "will," "potential," and similar terms and phrases to identify forward-looking statements in this press release. These statements are based on assumptions and estimates that management believes are reasonable based on currently available information; however, management's assumptions and the Company's future performance are both subject to a wide range of business risks and uncertainties, and there is no assurance that these goals and projections can or will be met. Any number of factors could cause actual results to differ materially from those in the forward-looking statements, including, but not limited to, the timing and extent of changes in demand for the Company's products, the availability and price of ingredients necessary to manufacture such products, and the outcome of any current or future litigation regarding such products or similar products of competitors. Please see our Risk Factor disclosures included in our Registration Statement on Form S-1, as amended, initially filed with the Securities and Exchange Commission on April 30, 2013, and in subsequent filings with the Securities and Exchange Commission. All future written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. The forward-looking statements herein speak as of the date of this press release. We undertake no obligation to update any information contained herein or to publicly release the results of any revisions to any forward-looking statements that may be made to reflect events or circumstances that occur, or that we become aware of, after the date of this press release.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2632958